FAM167B Inhibitors
FAM167B Inhibitors encompass chemical compounds that diminish the functional activity of FAM167B. Rapamycin, an mTOR inhibitor, disrupts the mTORC1 complex and downregulates processes potentially regulated by FAM167B, thus attenuating the signaling cascades in which FAM167B may participate. Similarly, LY 294002 and Wortmannin, both PI3K inhibitors, hinder the PI3K/AKT signaling pathway, which is pivotal for numerous cellular functions; their action would lead to a decrease in FAM167B-related signaling activities, should FAM167B be involved in this pathway. Another level of control is exerted by MAPK pathway inhibitors such as SB 203580, PD 98059, SP600125, and U0126, which block key kinases like p38 MAPK, MEK, and JNK. These inhibitors would suppress the functional activity of FAM167B if it is related to stress response, inflammation, or other cellular processes modulated by the MAPK family. Brefeldin A's disruption of vesicle trafficking could also impact FAM167B functionality if it is associated with intracellular transport, whereas Cyclosporin A and Okadaic Acid might alter FAM167B's role in T-cell activation or other phosphorylation-dependent signaling pathways by inhibiting calcineurin and protein phosphatases 1 and 2A, respectively.
Staurosporine's broad kinase inhibition could lead to a decrease in phosphorylation events within pathways involving FAM167B, thus indirectly inhibiting its activity. Additionally, the glycolysis inhibitor 2-Deoxy-D-glucose could restrict the energy supply and biosynthetic precursors necessary for FAM167B's engagement in cellular processes, indirectly leading to diminished functional activity. These chemical inhibitors collectively target various biochemical pathways and cellular processes that either directly or indirectly lead to the inhibition of FAM167B, without affecting its transcription or translation, but by hindering the specific signaling pathways or biological functions it is directly involved in. Each compound's inhibitory mechanism contributes to a concerted diminution of FAM167B's functional activity through multi-faceted interference in its associated pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that directly binds to the mTORC1 complex, leading to the downregulation of downstream processes that may be regulated by FAM167B. As FAM167B is potentially involved in cell signaling pathways, inhibition of mTOR would diminish the signaling cascades in which FAM167B may participate. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that prevents phosphatidylinositol 3,4,5-triphosphate production, leading to the inhibition of the AKT signaling pathway. Since FAM167B may be involved in the PI3K/AKT pathway, LY 294002 would thus lead to a decrease in FAM167B-related signaling activities. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, wortmannin binds irreversibly to PI3K, reducing AKT activation. This would indirectly diminish the functional activity of FAM167B if it is involved in the PI3K/AKT signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK, SB 203580 impedes the MAPK pathway, which may affect the functional activity of FAM167B if it plays a role in stress response or inflammation processes that p38 MAPK is involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that blocks MAPK/ERK pathway activation. If FAM167B is associated with the MAPK/ERK pathway, PD 98059 would result in a reduction of FAM167B functional activity by hindering the pathway's signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK family. By inhibiting JNK activity, SP600125 would diminish the functional activity of FAM167B if it is involved in cellular processes such as apoptosis or proliferation regulated by the JNK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, U0126 would inhibit the MAPK/ERK pathway, potentially diminishing the functional activity of FAM167B if it is implicated in this signaling cascade. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (Arf), Brefeldin A disrupts vesicle trafficking and may impact the functional activity of FAM167B by influencing intracellular transport processes that FAM167B could be involved with. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressant that inhibits calcineurin, Cyclosporin A could lead to a decrease in FAM167B functional activity if FAM167B is involved in T-cell activation or other calcineurin-mediated signaling pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
A potent inhibitor of protein phosphatases 1 and 2A, Okadaic Acid could diminish the dephosphorylation of proteins within pathways where FAM167B is active, altering its functional activity indirectly. | ||||||